THE Canadian government is looking to amend its drug pricing regulations to better protect Canadians from paying excessive prices for patented drugs, according to a report from the Regulatory Affairs Professionals Society.
Canada says its Patented Medicine Prices Review Board (PMPRB) compares Canada's prices with seven other countries, including the US, to determine if it is over-paying for medications.
Under the new proposal Canada would no longer use US or Switzerland as comparators and would add seven other countries: Australia, Belgium, Japan, Netherlands, Norway, South Korea and Spain.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 May 17